Smoking and the risk for bipolar disorder: evidence from a bidirectional Mendelian randomisation study.

CONCLUSIONS: These findings suggest that smoking initiation and lifetime smoking are likely to be a causal risk factor for developing bipolar disorder. We found some evidence that liability to bipolar disorder increased smoking heaviness. Given that smoking is a modifiable risk factor, these findings further support investment into smoking prevention and treatment in order to reduce mental health problems in future generations. DECLARATION OF INTEREST: W.v.d.B received fees in the past 3 years from Indivior, C&A Pharma, Opiant and Angelini. G.M.G. is a National Institute for Health Research (NIHR) Emeritus Senior Investigator, holds shares in P1vital and has served as consultant, advisor or CME speaker in the past 3 years for Allergan, Angelini, Compass Pathways, MSD, Lundbeck (/Otsuka and /Takeda), Medscape, Minervra, P1Vital, Pfizer, Sage, Servier, Shire and Sun Pharma. PMID: 31526406 [PubMed - as supplied by publisher]
Source: The British Journal of Psychiatry for Mental Science - Category: Psychiatry Tags: Br J Psychiatry Source Type: research

Related Links:

ie IB Abstract The aim of the 25 and Up (25Up) study was to assess a wide range of psychological and behavioral risk factors behind mental illness in a large cohort of Australian twins and their non-twin siblings. Participants had already been studied longitudinally from the age of 12 and most recently in the 19Up study (mean age = 26.1 years, SD = 4.1, range = 20-39). This subsequent wave follows up these twins several years later in life (mean age = 29.7 years, SD = 2.2, range =  22-44). The resulting data set enables additional detailed investigations of genetic pathways underlying psychiatr...
Source: Twin Research and Human Genetics - Category: Genetics & Stem Cells Authors: Tags: Twin Res Hum Genet Source Type: research
Yesterday the Food and Drug Administration (FDA) approved Vraylar (cariprazine) for the treatment of depressive episodes in adults with bipolar I disorder. This expanded indication means Vraylar, a dopamine and serotonin partial agonist, is now approved to treat depressive, manic, and mixed episodes of bipolar I disorder. Vraylar, which is manufactured by Allergan, is also approved for the treatment of schizophrenia in adults.The drug ’s expanded indication is based on results from three clinical trials (RGH-MD-53,RGH-MD-54, andRGH-MD-56), which evaluated Vraylar once daily versus placebo in adults with bipolar depre...
Source: Psychiatr News - Category: Psychiatry Tags: Allergan bipolar depression bipolar disorder cariprazine depressive episode Stephen Stahl Vraylar Source Type: research
Vraylar is also approved for schizophrenia in adults and for manic or mixed episodes associated with bipolar I disorder
Source: PharmaManufacturing.com - Category: Pharmaceuticals Source Type: news
Allergan Plc's Vraylar won U.S. regulatory approval to treat depressive episodes of bipolar I disorder, expanding its scope of treatment to a full spectrum of symptoms related to the condition, the company said on Monday.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news
DUBLIN and BUDAPEST, Hungary, May 28, 2019 /PRNewswire/ -- Allergan plc (NYSE: AGN) and Gedeon Richter Plc. today announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental New Drug Application (sNDA) for Vraylar...
Source: Drugs.com - New Drug Approvals - Category: Drugs & Pharmacology Source Type: news
DUBLIN and BUDAPEST, Hungary, May 28, 2019 /PRNewswire/ -- Allergan plc (NYSE: AGN) and Gedeon Richter Plc. today announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental New Drug Application (sNDA) for Vraylar...
Source: Drugs.com - New Drug Approvals - Category: Drugs & Pharmacology Source Type: news
Joseph D. Romano1,2,3,4 and Nicholas P. Tatonetti1,2,3,4* 1Department of Biomedical Informatics, Columbia University, New York, NY, United States 2Department of Systems Biology, Columbia University, New York, NY, United States 3Department of Medicine, Columbia University, New York, NY, United States 4Data Science Institute, Columbia University, New York, NY, United States The discovery of new pharmaceutical drugs is one of the preeminent tasks—scientifically, economically, and socially—in biomedical research. Advances in informatics and computational biology have increased productivity at many stag...
Source: Frontiers in Genetics - Category: Genetics & Stem Cells Source Type: research
Conclusion: Young SMILES captures a broad age range and level of need for CAPRI and can be evaluated with quantifiable child-centered outcomes. In line with current policy directives, this is the first UK-based, multi-context intervention to improve QoL in this population. Implementation and referral mechanisms are currently being evaluated in a multi-site feasibility trial. Introduction Children and adolescents living with parental mental illness (CAPRI) are poorly provided for in current social care and educational settings (1, 2). Children and young people (CYP) growing up in families affected by parental mental h...
Source: Frontiers in Psychiatry - Category: Psychiatry Source Type: research
CONCLUSIONS: MDD is highly prevalent among nursing homes residents without dementia. Efforts towards prevention, early recognition and management of MDD in this population are warranted.Declaration of interestE.V. has received grants and served as consultant, advisor or continuing medical education speaker for the following organisations: AB-Biotics, Allergan, Angelini, AstraZeneca, Bristol-Myers Squibb, Dainippon Sumitomo Pharma, Farmindustria, Ferrer, Gedeon Richter, Glaxo-Smith-Kline, Janssen, Lundbeck, Otsuka, Pfizer, Roche, Sanofi-Aventis, Servier, Shire, Sunovion, Takeda, the Brain and Behaviour Foundation, the Spani...
Source: The British Journal of Psychiatry for Mental Science - Category: Psychiatry Tags: Br J Psychiatry Source Type: research
Many patients who take the antipsychotic olanzapine for psychiatric disorders are known to experience significant weight gain. Astudy in AJP in Advance now suggests that olanzapine may be able to help adults with anorexia gain some weight, but it does not appear to reduce psychological symptoms associated with the disorder.“We found a weight gain effect associated with olanzapine, but it was more modest than the significant, usually undesirable, weight gain seen when olanzapine is used to treat other disorders,” Evelyn Attia, M.D., of Columbia University Irving Medical Center and colleagues wrote. The find...
Source: Psychiatr News - Category: Psychiatry Tags: ajp in advance anorexia antipsychotic Evelyn Attia olanzapine weight gain Yale-Brown Obsessive Compulsive Scale Source Type: research
More News: Allergy | Bipolar | Mania | Men | National Institute for Health Research (NIHR) | Pfizer | Pharmaceuticals | Psychiatry | Science | Smokers | Statistics | Study | UK Health